Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyoko Yamaguchi

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Cancer Letters|February 12, 2022
Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusionsMamoru Ito, Michitaka Nakano, Hiroshi Ariyama, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2023
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactionsKoki Uehara, Kenro Tanoue, Kyoko Yamaguchi, et al.
Cancer Science|September 7, 2018
PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancerMichitaka Nakano, Mamoru Ito, Risa Tanaka, et al.
JCO Precision Oncology|May 15, 2024
Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric CancerKyoko Yamaguchi, Mamoru Ito, Taichi Isobe, et al.
Japanese Journal of Clinical Oncology|November 8, 2025
Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumorsAya Takigawa, Kenji Tsuchihashi, Kenta Nio, et al.
FEBS Open Bio|November 19, 2019
Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancerHirofumi Ohmura, Mamoru Ito, Keita Uchino, et al.
Nature Human Behaviour|July 24, 2019
Patterns of paternal investment predict cross-cultural variation in jealous responseBrooke A Scelza, Sean P Prall, Tami Blumenfield, et al.
Cancer Research|October 8, 2009
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinasesFawn Qian, Stefan Engst, Kyoko Yamaguchi, et al.
Molecular Cancer Therapeutics|September 20, 2011
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthF Michael Yakes, Jason Chen, Jenny Tan, et al.
Scientific Reports|December 2, 2020
Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicinKenji Tsuchihashi, Hitoshi Kusaba, Tomoyasu Yoshihiro, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Cancer Letters|February 12, 2022
Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusionsMamoru Ito, Michitaka Nakano, Hiroshi Ariyama, et al.
Cancer Immunology, Immunotherapy : CII|August 7, 2023
Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactionsKoki Uehara, Kenro Tanoue, Kyoko Yamaguchi, et al.
Cancer Science|September 7, 2018
PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancerMichitaka Nakano, Mamoru Ito, Risa Tanaka, et al.
JCO Precision Oncology|May 15, 2024
Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2-Positive Advanced Gastric CancerKyoko Yamaguchi, Mamoru Ito, Taichi Isobe, et al.
Japanese Journal of Clinical Oncology|November 8, 2025
Clinical outcomes and genomic alterations in patients with metastatic malignant phyllodes tumorsAya Takigawa, Kenji Tsuchihashi, Kenta Nio, et al.
FEBS Open Bio|November 19, 2019
Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancerHirofumi Ohmura, Mamoru Ito, Keita Uchino, et al.
Nature Human Behaviour|July 24, 2019
Patterns of paternal investment predict cross-cultural variation in jealous responseBrooke A Scelza, Sean P Prall, Tami Blumenfield, et al.
Cancer Research|October 8, 2009
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinasesFawn Qian, Stefan Engst, Kyoko Yamaguchi, et al.
Molecular Cancer Therapeutics|September 20, 2011
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthF Michael Yakes, Jason Chen, Jenny Tan, et al.
Scientific Reports|December 2, 2020
Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicinKenji Tsuchihashi, Hitoshi Kusaba, Tomoyasu Yoshihiro, et al.
Pageof 5